CDC Recommendations for Hepatitis B Screening and Testing-United States, 2022, 16981 [2023-05715]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 54 / Tuesday, March 21, 2023 / Notices
that the use of non-compete agreements
has a tendency to harm competition and
workers, but fails to provide facts to
support the hypothesized outcome.
Similar to the Commission’s complaints
against O–I Glass and Ardagh Group,
the complaint against Anchor Glass
suffers from several omissions. It does
not allege that the company’s noncompete provisions are unreasonable
based on their temporal length, subject
matter, or geographic scope; neither
does it allege that the non-compete
clauses were enforced. The complaint
does not make factual allegations
regarding the inability of a competing
rival in the glass container industry to
enter or expand. While the complaint
alleges that the non-compete clauses
reduce employee mobility, thereby
leading to lower wages, reduced
benefits, and less favorable working
conditions, the complaint does not
identify a relevant market for particular
types of labor and fails to allege a
market effect on wages or other terms of
employment.
For the reasons outlined here and
explained in detail in my January 2023
statement, I dissent.
[FR Doc. 2023–05701 Filed 3–20–23; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0044]
CDC Recommendations for Hepatitis B
Screening and Testing—United States,
2022
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: General notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), within
the Department of Health and Human
Services (HHS), announces the
availability of the final CDC
Recommendations for Hepatitis B
Screening and Testing—United States,
2022.
DATES: The final document was
published as an MMWR Reports &
Recommendations on March 10, 2023.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
ftc_gov/pdf/p221202sec5enforcementpolicy
statement_002.pdf; Christine S. Wilson, Dissenting
Statement Regarding the ‘‘Policy Statement
Regarding the Scope of Unfair Methods of
Competition Under Section 5 of the Federal Trade
Commission Act’’ (Nov. 10, 2022), https://
www.ftc.gov/system/files/ftc_gov/pdf/
P221202Section5PolicyWilsonDissentStmt.pdf.
VerDate Sep<11>2014
19:23 Mar 20, 2023
Jkt 259001
The document may be
found in the docket at
www.regulations.gov, Docket No. CDC–
2022–0044 and at https://www.cdc.gov/
mmwr/volumes/72/rr/rr7201a1.htm?s_
cid=rr7201a1_w.
FOR FURTHER INFORMATION CONTACT: Erin
Conners, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop U12–3, Atlanta, GA 30329.
Telephone: 404–639–8000; Email:
DVHpolicy@cdc.gov.
SUPPLEMENTARY INFORMATION: In 2022,
CDC determined that CDC
Recommendations for Hepatitis B
Screening and Testing—United States,
2022 constituted influential scientific
information (ISI) that will have a clear
and substantial impact on important
public policies and private sector
decisions. Under the Information
Quality Act, Public Law 106–554,
federal agencies are required to conduct
peer review of the information by
specialists in the field who were not
involved in the development of these
recommendations. CDC solicited
nominations for reviewers from the
American Association for the Study of
Liver Diseases (AASLD), Infectious
Diseases Society of America (IDSA) and
American College of Physicians (ACP).
Five clinicians with expertise in
hepatology, gastroenterology, internal
medicine, infectious diseases, and/or
pediatrics provided structured peer
reviews. A list of peer reviewers and
CDC’s responses to peer review
comments are available at CDC’s Viral
Hepatitis Influential Scientific
Information web page at https://
www.cdc.gov/hepatitis/policy/isireview/
index.htm.
In addition, on April 4, 2022, CDC
published a notice in the Federal
Register (87 FR 19516–19517) to obtain
public comment on the draft
recommendations for hepatitis B
screening and testing. The comment
period closed on June 3, 2022. CDC
received comments from 28 commenters
on the draft recommendations
document. Public commenters included
those from academia, the health care
sector, advocacy groups, professional
organizations, industry, the public, and
a consulting group.
Many of the comments expressed
support for the recommendations. Other
comments related to the 3-panel test
recommendation, inclusion of hepatitis
D information, the hepatitis B
prevalence estimate, modifying testing
and vaccination language, adding
scientific references, and making other
minor language modifications. CDC
addressed these comments by
correcting, clarifying, or updating
ADDRESSES:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
16981
content in the final recommendations. A
summary of public comments and
CDC’s response can be found in the
Documents tab of the docket.
Tiffany Brown,
Acting Executive Secretary, Centers for
Disease Control and Prevention.
[FR Doc. 2023–05715 Filed 3–20–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3434–FN]
Medicare and Medicaid Programs:
Application From the Accreditation
Commission for Health Care, Inc. for
Continued Approval of Its End-Stage
Renal Disease (ESRD) Accreditation
Program
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This final notice announces
our decision to approve the
Accreditation Commission for Health
Care, Inc for continued recognition as a
national accrediting organization for
end stage renal disease facilities that
wish to participate in the Medicare or
Medicaid programs.
DATES: The decision announced in this
final notice is applicable on April 11,
2023 through April 10, 2029.
FOR FURTHER INFORMATION CONTACT:
Joy Webb, (410) 786–1667.
Caecilia Blondiaux, (410) 786–2190.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services from an end stage renal disease
(ESRD) facility provided certain
requirements are met. Section 1881(b) of
the Social Security Act (the Act),
establishes distinct criteria for facilities
seeking designation as an ESRD facility.
Regulations concerning provider
agreements are at 42 CFR part 489 and
those pertaining to activities relating to
the survey and certification of facilities
are at 42 CFR part 488. The regulations
at 42 CFR part 494 specify the minimum
conditions that an ESRD facility must
meet to participate in the Medicare
program.
Generally, to enter into an agreement,
an ESRD facility must first be certified
by a state survey agency (SA) as
complying with the conditions or
requirements set forth in part 494 of our
E:\FR\FM\21MRN1.SGM
21MRN1
]]>Agencies
[Federal Register Volume 88, Number 54 (Tuesday, March 21, 2023)]
[Notices]
[Page 16981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-05715]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0044]
CDC Recommendations for Hepatitis B Screening and Testing--United
States, 2022
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: General notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), within
the Department of Health and Human Services (HHS), announces the
availability of the final CDC Recommendations for Hepatitis B Screening
and Testing--United States, 2022.
DATES: The final document was published as an MMWR Reports &
Recommendations on March 10, 2023.
ADDRESSES: The document may be found in the docket at
www.regulations.gov, Docket No. CDC-2022-0044 and at https://www.cdc.gov/mmwr/volumes/72/rr/rr7201a1.htm?s_cid=rr7201a1_w.
FOR FURTHER INFORMATION CONTACT: Erin Conners, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop U12-3, Atlanta,
GA 30329. Telephone: 404-639-8000; Email: [email protected].
SUPPLEMENTARY INFORMATION: In 2022, CDC determined that CDC
Recommendations for Hepatitis B Screening and Testing--United States,
2022 constituted influential scientific information (ISI) that will
have a clear and substantial impact on important public policies and
private sector decisions. Under the Information Quality Act, Public Law
106-554, federal agencies are required to conduct peer review of the
information by specialists in the field who were not involved in the
development of these recommendations. CDC solicited nominations for
reviewers from the American Association for the Study of Liver Diseases
(AASLD), Infectious Diseases Society of America (IDSA) and American
College of Physicians (ACP). Five clinicians with expertise in
hepatology, gastroenterology, internal medicine, infectious diseases,
and/or pediatrics provided structured peer reviews. A list of peer
reviewers and CDC's responses to peer review comments are available at
CDC's Viral Hepatitis Influential Scientific Information web page at
https://www.cdc.gov/hepatitis/policy/isireview/index.htm.
In addition, on April 4, 2022, CDC published a notice in the
Federal Register (87 FR 19516-19517) to obtain public comment on the
draft recommendations for hepatitis B screening and testing. The
comment period closed on June 3, 2022. CDC received comments from 28
commenters on the draft recommendations document. Public commenters
included those from academia, the health care sector, advocacy groups,
professional organizations, industry, the public, and a consulting
group.
Many of the comments expressed support for the recommendations.
Other comments related to the 3-panel test recommendation, inclusion of
hepatitis D information, the hepatitis B prevalence estimate, modifying
testing and vaccination language, adding scientific references, and
making other minor language modifications. CDC addressed these comments
by correcting, clarifying, or updating content in the final
recommendations. A summary of public comments and CDC's response can be
found in the Documents tab of the docket.
Tiffany Brown,
Acting Executive Secretary, Centers for Disease Control and Prevention.
[FR Doc. 2023-05715 Filed 3-20-23; 8:45 am]
BILLING CODE 4163-18-P
